Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)
The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively e...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/20/21/5333 |
id |
doaj-7413e7a45feb4b24875d161364c7bd39 |
---|---|
record_format |
Article |
spelling |
doaj-7413e7a45feb4b24875d161364c7bd392020-11-25T02:50:05ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-10-012021533310.3390/ijms20215333ijms20215333Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90)Oi Wei Mak0Raina Chand1Jóhannes Reynisson2Ivanhoe K. H. Leung3School of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandSchool of Chemical Sciences, The University of Auckland, Private Bag 92019, Victoria Street West, Auckland 1142, New ZealandThe molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual screening and binding studies, we report our work in the identification and characterisation of novel isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further development of isoform-selective Hsp90 inhibitors.https://www.mdpi.com/1422-0067/20/21/5333hsp90virtual screeningintrinsic tryptophan fluorescenceligand bindingisoform-selective |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Oi Wei Mak Raina Chand Jóhannes Reynisson Ivanhoe K. H. Leung |
spellingShingle |
Oi Wei Mak Raina Chand Jóhannes Reynisson Ivanhoe K. H. Leung Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) International Journal of Molecular Sciences hsp90 virtual screening intrinsic tryptophan fluorescence ligand binding isoform-selective |
author_facet |
Oi Wei Mak Raina Chand Jóhannes Reynisson Ivanhoe K. H. Leung |
author_sort |
Oi Wei Mak |
title |
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) |
title_short |
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) |
title_full |
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) |
title_fullStr |
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) |
title_full_unstemmed |
Identification of Isoform-Selective Ligands for the Middle Domain of Heat Shock Protein 90 (Hsp90) |
title_sort |
identification of isoform-selective ligands for the middle domain of heat shock protein 90 (hsp90) |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2019-10-01 |
description |
The molecular chaperone heat shock protein 90 (Hsp90) is a current inhibition target for the treatment of diseases, including cancer. In humans, there are two major cytosolic isoforms of Hsp90 (Hsp90α and Hsp90β). Hsp90α is inducible and Hsp90β is constitutively expressed. Most Hsp90 inhibitors are pan-inhibitors that target both cytosolic isoforms of Hsp90. The development of isoform-selective inhibitors of Hsp90 may enable better clinical outcomes. Herein, by using virtual screening and binding studies, we report our work in the identification and characterisation of novel isoform-selective ligands for the middle domain of Hsp90β. Our results pave the way for further development of isoform-selective Hsp90 inhibitors. |
topic |
hsp90 virtual screening intrinsic tryptophan fluorescence ligand binding isoform-selective |
url |
https://www.mdpi.com/1422-0067/20/21/5333 |
work_keys_str_mv |
AT oiweimak identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90 AT rainachand identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90 AT johannesreynisson identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90 AT ivanhoekhleung identificationofisoformselectiveligandsforthemiddledomainofheatshockprotein90hsp90 |
_version_ |
1724740332944359424 |